Compare BIRK & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | TGTX |
|---|---|---|
| Founded | 1774 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | 399 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.5B |
| IPO Year | 2023 | 2008 |
| Metric | BIRK | TGTX |
|---|---|---|
| Price | $39.42 | $48.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $61.43 | $49.80 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $13.71 | $49.08 |
| Revenue Next Year | $14.30 | $26.69 |
| P/E Ratio | ★ $17.48 | $282.12 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.33 | $26.76 |
| 52 Week High | $53.53 | $59.30 |
| Indicator | BIRK | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 41.76 |
| Support Level | $37.57 | $45.37 |
| Resistance Level | $41.89 | $58.08 |
| Average True Range (ATR) | 1.80 | 2.11 |
| MACD | 0.12 | -0.48 |
| Stochastic Oscillator | 44.71 | 29.86 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.